- Home
- PLRX
as of 01-28-2026 1:19pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 93.3M | IPO Year: | 2020 |
| Target Price: | $3.79 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $12.88 | Next Earning Date: | 03-02-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered PLRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pliant Therapeutics Inc. (PLRX)
President and CEO
Avg Cost/Share
$1.28
Shares
89,375
Total Value
$114,400.00
Owned After
505,601
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.28
Shares
24,002
Total Value
$30,722.56
Owned After
297,214
SEC Form 4
Chief Human Resource Officer
Avg Cost/Share
$1.28
Shares
7,534
Total Value
$9,643.52
Owned After
44,847
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$1.28
Shares
6,917
Total Value
$8,853.76
Owned After
37,806
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Coulie Bernard | PLRX | President and CEO | Jan 20, 2026 | Sell | $1.28 | 89,375 | $114,400.00 | 505,601 | |
| Cummings Keith Lamont | PLRX | Chief Financial Officer | Jan 20, 2026 | Sell | $1.28 | 24,002 | $30,722.56 | 297,214 | |
| Cheung Lily | PLRX | Chief Human Resource Officer | Jan 20, 2026 | Sell | $1.28 | 7,534 | $9,643.52 | 44,847 | |
| Kuo Minnie | PLRX | Chief Operating Officer | Jan 20, 2026 | Sell | $1.28 | 6,917 | $8,853.76 | 37,806 |
Compare PLRX vs Leading Stocks
See how PLRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.